Bioequivalence Evaluation of a Folate-Supplemented Oral Contraceptive Containing Ethinylestradiol/Drospirenone/Levomefolate Calcium versus Ethinylestradiol/Drospirenone and Levomefolate Calcium Alone

被引：2
|
作者：
Herbert Wiesinger
Urte Eydeler
Frank Richard
Dietmar Trummer
Hartmut Blode
Beate Rohde
Konstanze Diefenbach
机构：
[1] Bayer HealthCare Pharmaceuticals,
[2] Scope International GmbH,undefined
[3] Nycomed GmbH — A Takeda Company,undefined
来源：
Clinical Drug Investigation | 2012年 / 32卷
关键词：
Folate; Folate Level; Folate Status; Study Drug Administration; Drospirenone;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Background: Neural tube defects (NTDs) are congenital malformations that occur during early embryonic development. Suboptimal maternal folate status is a well-known risk factor for the occurrence of NTDs, and periconceptional folic acid supplementation has been shown to reduce the risk of NTDs. Folate-supplemented oral contraceptives (OCs) offer a means of improving folate status in women of childbearing potential by increasing their likelihood of having raised folate levels at the time of conception.
引用
收藏
页码：673 / 684
页数：11
相关论文
共 17 条
  • [1] Bioequivalence study of an oral contraceptive containing ethinylestradiol/drospirenone/levomefolate calcium relative to ethinylestradiol/drospirenone and to levomefolate calcium alone
    Blode, Hartmut
    Klipping, Christine
    Richard, Frank
    Trummer, Dietmar
    Rohde, Beate
    Diefenbach, Konstanze
    CONTRACEPTION, 2012, 85 (02) : 177 - 184
  • [2] EE-drospirenone-levomefolate calcium versus EE-drospirenone
    Diefenbach, Konstanze
    Trummer, Dietmar
    Ebert, Frank
    Lissy, Michael
    Koch, Manuela
    Rohde, Beate
    Blode, Hartmut
    INTERNATIONAL JOURNAL OF WOMENS HEALTH, 2013, 5 : 149 - 163
  • [3] Effects of low dose oral contraceptive pill containing drospirenone/ethinylestradiol in patients with endometrioma
    Taniguchi, Fuminori
    Enatsu, Akiko
    Ota, Ikuko
    Toda, Toshiko
    Arata, Kazuya
    Harada, Tasuku
    EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 2015, 191 : 116 - 120
  • [4] Evaluation of effects of an oral contraceptive containing ethinylestradiol combined with drospirenone on adrenal steroidogenesis in hyperandrogenic women with polycystic ovary syndrome
    De Leo, Vincenzo
    Morgante, Giuseppe
    Piomboni, Paola
    Musacchio, Maria Concetta
    Petraglia, Felice
    Cianci, Antonio
    FERTILITY AND STERILITY, 2007, 88 (01) : 113 - 117
  • [5] Effect of an oral contraceptive containing drospirenone and ethinylestradiol on general well-being and fluid-related symptoms
    Apter, D
    Borsos, A
    Baumgärtner, W
    Melis, GB
    Vexiau-Robert, D
    Colligs-Hakert, A
    Palmer, M
    Kelly, S
    EUROPEAN JOURNAL OF CONTRACEPTION AND REPRODUCTIVE HEALTH CARE, 2003, 8 (01): : 37 - 51
  • [6] A historical cycle control comparison of two drospirenone-containing combined oral contraceptives: ethinylestradiol 30 μg/drospirenone 3 mg administered in a 21/7 regimen versus ethinylestradiol 20 μg/drospirenone 3 mg administered in a 24/4 regimen
    Marr, Joachim
    Gerlinger, Christoph
    Kunz, Michael
    EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 2012, 162 (01) : 91 - 95
  • [7] Efficacy and safety of a low-dose 24-day combined oral contraceptive containing 20 μg ethinylestradiol and 3 mg drospirenone
    Bachmann, G
    Sulak, PJ
    Sampson-Landers, C
    Benda, N
    Marr, J
    CONTRACEPTION, 2004, 70 (03) : 191 - 198
  • [8] Efficacy and Safety of a Low-Dose 21-Day Combined Oral Contraceptive Containing Ethinylestradiol 20μg and Drospirenone 3mg
    D. Cibula
    U. Karck
    H. G. Weidenhammer
    J. Kunz
    S. Alincic
    J. Marr
    Clinical Drug Investigation, 2006, 26 : 143 - 150
  • [9] Efficacy and safety of a low-dose combined oral contraceptive containing drospirenone 3 mg and ethinylestradiol 20 mcg in a 24/4-day regimen
    Laszlo Hernadi
    Marr, Joachim
    Trummer, Dietmar
    De Leo, Vincenzo
    Petraglia, Felice
    CONTRACEPTION, 2009, 80 (01) : 18 - 24
  • [10] Effect of an oral contraceptive containing 30 μg ethinylestradiol plus 3 mg drospirenone on body composition of young women affected by premenstrual syndrome with symptoms of water retention
    Fruzzetti, Franca
    Lazzarini, Veronica
    Ricci, Cabiria
    Quirici, Barbara
    Gambacciani, Marco
    Paoletti, Anna Maria
    Genazzani, Andrea Riccardo
    CONTRACEPTION, 2007, 76 (03) : 190 - 194
12